BCR and acute lymphoblastic leukemia: Studies with dasatinib, another TKI, in combination with anti-PD-1 eliminated BCR::ABL+ ALL cells, prolonged survival, and induced anti-leukemic immune memory upon rechallenge in syngeneic mice (90).